Opendata, web and dolomites

BGCI

Bacterial Ghost Cancer Immunotherapy - A new standard in tumour therapy based on the bacterial ghost platform technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "BGCI" data sheet

The following table provides information about the project.

Coordinator
BIOTECH INNOVATION RESEARCH DEVELOPMENT AND CONSULTING GMBH & CO KG 

Organization address
address: HAUPTSTRASSE 88
city: KRITZENDORF
postcode: 3420
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.bird-c.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOTECH INNOVATION RESEARCH DEVELOPMENT AND CONSULTING GMBH & CO KG AT (KRITZENDORF) coordinator 50˙000.00

Map

 Project objective

MMalignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/ IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strategies for cancer including surgery, chemotherapy and targeted molecular therapy still do not guarantee complete elimination of the disease. In addition, cancer cells exhibited high capability to escape from immunosurveillance after applied treatment which was confirmed with frequently occurred relapse of disease. BIRD-C have developed Bacterial Ghost Cancer Immunotherapy (BGCI) - a novel personalised medicine approach towards vaccination against tumours. BIRD-C’s therapeutic cancer vaccines are based on personalised dendritic cells-based cancer immunotherapy that targets the tumour microenvironment using Bacterial Ghosts (BGs), the proprietary platform technology of BIRD-C. The tumour therapy strategy is to (re)stimulate the patient immune system to revert the tumour evasion and build strong humoral and cellular immune responses against patient-specific tumour antigens. Obtained results show that BGCI can generate effective response to tumours and indicate novel prospective methods for cellular cancer immunotherapy. This approach has been tested in a form of advanced personalised cancer therapy and has improved the survival of patients with solid tumours. During the project, BIRD-C will develop the manufacturing procedure and commercial scale-up strategy and also conduct a multi-centre trial with patients affected by various forms of cancer at different stages of progression to determine the tolerability and effectiveness of the treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGCI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGCI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More